HC Wainwright restated their buy rating on shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) in a research note issued to investors on Thursday. The firm currently has a $5.00 price target on the stock.
Other analysts have also recently issued reports about the stock. Rodman & Renshaw assumed coverage on shares of HTG Molecular Diagnostics in a research note on Monday, August 22nd. They issued a buy rating and a $5.00 price objective for the company. Zacks Investment Research upgraded shares of HTG Molecular Diagnostics from a sell rating to a hold rating in a research note on Wednesday, July 13th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $5.25.
HTG Molecular Diagnostics (NASDAQ:HTGM) opened at 2.63 on Thursday. The firm’s market capitalization is $18.54 million. HTG Molecular Diagnostics has a 12 month low of $2.03 and a 12 month high of $6.03. The firm’s 50-day moving average is $2.51 and its 200 day moving average is $2.65.
HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its earnings results on Tuesday, August 9th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.95) by $0.03. Equities analysts predict that HTG Molecular Diagnostics will post ($3.58) earnings per share for the current year.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.